ACT - AdvisorShares Vice ETF

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
26.99
+0.36 (+1.35%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close26.63
Open26.90
Bid0.00 x 0
Ask0.00 x 0
Day's Range26.71 - 26.99
52 Week Range24.98 - 29.50
Volume23,525
Avg. Volume33,357
Net Assets7.85M
NAV26.15
PE Ratio (TTM)N/A
YieldN/A
YTD ReturnN/A
Beta (3y)0.00
Expense Ratio (net)0.00%
Inception Date2017-12-11
Trade prices are not sourced from all markets
  • The Wall Street Journal7 days ago

    [$$] Judge Signals He Will Approve $290 Million Settlement Between Allergan Shareholders and Pershing, Valeant

    A federal judge signaled he would approve a $290 million settlement reached by Pershing Square, Valeant and the shareholders of Allergan who had alleged the two firms improperly profited from their failed ...

  • What Investors Need to Know About Marijuana ETFs
    Zacks12 days ago

    What Investors Need to Know About Marijuana ETFs

    Marijuana stocks and ETFs have been soaring despite regulatory uncertainty; here is what investors need to know.

  • MarketWatch12 days ago

    Ackman’s Pershing Square cuts hedge-fund fees due to lawsuit settlement

    Pershing Square Holdings, the hedge fund operated by noted activist investor Bill Ackman, on Wednesday announced it was slashing its management fees, a move related to the settlement of two class-action ...

  • Pot Stock Plays Fall, But Here's Why Jeff Sessions May Not Matter Much
    Investor's Business Daily19 days ago

    Pot Stock Plays Fall, But Here's Why Jeff Sessions May Not Matter Much

    Exchange traded funds tied to marijuana skidded on Thursday on a report that Attorney General Jeff Sessions planned to roll back the measure that encouraged more states in recent years to legalize usage of the plant. 

  • Forbes25 days ago

    Bill Ackman And Valeant Settle Allergan Insider Trading Lawsuit For $290 Million

    Hedge funder Bill Ackman and Valeant Pharmaceuticals will pay $290 million to settle claims from shareholders in Allergan they engaged in insider trading when pressing a takeover of the botox-maker in 2014. The settlement means Valeant likely cost Pershing $4 billion.

  • The Wall Street Journal25 days ago

    [$$] Pershing Square, Valeant to Pay $290 Million to Settle Allergan Suit

    Pershing Square Capital Management and Valeant Pharmaceuticals are paying $290 million to settle a lawsuit that alleged their trading in Allergan was illegal, allowing William Ackman to put behind him ...

  • Reuters25 days ago

    Pershing Square, Valeant arrive at settlement split for Allergan lawsuit

    Pershing Square said it decided to raise its share of the settlement to 66.8 percent, or $193.75 million, in a bid to quickly wind up the litigation, which it claimed had "no merit". "We decided, however, that it was in the best interest of our investors to settle the case now instead of continuing to spend substantial time and resources pursuing the litigation," said Pershing Square CEO Bill Ackman. The hedge fund said Valeant will now pay around 33 percent, or $96.25 million, of the settlement costs.

  • Pershing Square, Valeant to Pay $290 Million to End Lawsuit
    Bloomberg25 days ago

    Pershing Square, Valeant to Pay $290 Million to End Lawsuit

    Activist investor Bill Ackman’s Pershing Square Holdings Ltd. and Valeant Pharmaceuticals International Inc. agreed to pay $290 million to settle investor claims that they engaged in insider trading in ...

  • MarketWatch26 days ago

    Valeant says parties in Allergan litigation have agreed to resolve claims of $290 million

    Valeant Pharmaceuticals International Inc. said Friday that all parties in the Allergan Inc. shareholder securities litigation have agreed to resolve the claims that total $290 million, subject to court ...

  • Rush for Marijuana ETFs Getting Stronger
    Zacks26 days ago

    Rush for Marijuana ETFs Getting Stronger

    Teucrium plans for an Emerging Medical Agriculture Index Fund. Does this hint at a marijuana ETF?

  • The Wall Street Journal29 days ago

    [$$] Judge Sides Against Ackman and Valeant in Preliminary Allergan Ruling

    A preliminary ruling from a federal judge against William Ackman, his hedge fund and Valeant in an insider-trading case could trigger a settlement between the activist investor and shareholders of Allergan....

  • ETF Databaselast month

    This Week's ETF Launches: Introducing the First Quadruple-Leveraged Products

    Triple-leveraged ETFs – funds that mainly use futures to ratchet up the exposure to a specific asset – have long been considered one of Wall Street’s riskiest products. This week, those funds take a back seat to the newly launched quadruple-leveraged exchange-traded notes brought to the market by Citigroup.

  • ETF Trendslast month

    Sin Is In With New Vice ETF

    AdvisorShares, an exchange traded fund provider known for its actively managed investment options, has launched a new ETF that capitalizes on vice and also one among the first to include targeted exposure ...

  • PR Newswirelast month

    AdvisorShares Delivers Alcohol, Cannabis & Tobacco Exposure with New Actively Managed ETF

    BETHESDA, Md., Dec. 11, 2017 /PRNewswire/ -- AdvisorShares, a leading sponsor of actively managed exchange-traded funds (ETFs), announced today that the AdvisorShares Vice ETF (Ticker: ACT) will begin trading on Tuesday, December 12, 2017. ACT becomes the first ETF – among both passively managed and actively managed strategies – that provides concentrated exposure to select companies associated with alcohol, cannabis and tobacco. ACT's portfolio management team carries extensive experience in the capital markets and a well-established expertise of investing in this area of the equity markets, which includes the founder and original portfolio manager of the Vice Fund mutual fund (VICEX).

  • Reuters6 months ago

    Drugmaker Teva looks to sell Medis business to help cut debt

    Teva Pharmaceutical Industries , the world's largest generic drugmaker, said on Wednesday it was looking for a buyer for its Medis business as it sells assets to pare down its debt burden. Teva, which last week reported a drop in second-quarter results and cut its outlook and dividend, acquired Iceland-based Medis as part of its acquisition of Actavis last year. "Teva is looking at every opportunity to focus our business and streamline operations, processes and structure," Teva said in an emailed statement to Reuters.

  • Reuters7 months ago

    UK Supreme Court rules in favor of Lilly's Alimta patents

    Eli Lilly and Co won a years-long patent dispute with Actavis on Friday after the UK Supreme Court ruled that the generic drugmaker's versions of Lilly's top-selling cancer drug Alimta directly infringe on certain Lilly patents in Britain, France, Italy and Spain. Teva Pharmaceutical Industries Ltd owns the generic versions of Alimta in question after buying Allergan Plc's generic business Actavis last August.

  • Associated Press7 months ago

    UK Supreme Court rules in Eli Lilly's favor in drug dispute

    LONDON (AP) — Britain's Supreme Court has ruled in favor of Eli Lilly and Co. in a patent dispute with generic drug-maker Actavis over Lilly's Alimta cancer treatment.

  • TheStreet.com7 months ago

    UK Supreme Court Rules in Lilly's Favor: Actavis Infringed on European Vitamins Patents

    Lilly sued Actavis, saying its generic product would still infringe on Lilly's vitamin regimens regardless of any dilution.

  • Eli Lilly Wins Cancer Drug Patent Case at U.K. Supreme Court
    Bloomberg7 months ago

    Eli Lilly Wins Cancer Drug Patent Case at U.K. Supreme Court

    Eli Lilly & Co. won a patent dispute with Actavis at the U.K.’s top court, marking a victory in a long-running legal campaign to defend its third best-selling drug, Alimta, from rival products.

  • Reuters8 months ago

    Teva Q1 profit tops estimates, revenue up on Actavis deal

    Israel-based Teva Pharmaceutical Industries reported a smaller-than-expected fall in first-quarter profit on Thursday, with sales boosted by its $40.5 billion acquisition last year of generics drug business Actavis. Teva was left without a permanent chief executive in February after Erez Vigodman stepped down, leaving new management to try to restore confidence in the world's biggest generic drugmaker after a series of missteps. Teva on Thursday named Michael McClellan as interim CFO, effective July 1.

  • Allergan posts loss as it writes down Teva holdings
    Reuters9 months ago

    Allergan posts loss as it writes down Teva holdings

    Allergan sold its generics business Actavis to Teva in August 2016 for $33 billion in cash and 100 million shares of the Israeli generic drugmaker, worth around $5.3 billion at the time. Under the terms of the deal, Allergan agreed to hold on to the shares for at least one year. Teva has struggled since then, and the company's chief executive stepped down in February after sharp criticism for a string of costly acquisitions and delayed drug launches.

  • Reuters9 months ago

    Allergan posts loss as it writes down Teva holdings

    Botox-maker Allergan Plc posted a first-quarter loss on Tuesday as it took a nearly $2 billion write-down on the value of its stake in Teva Pharmaceutical Industries, which has lost more than 40 percent of its value since last year. Allergan sold its generics business Actavis to Teva in August 2016 for $33 billion in cash and 100 million shares of the Israeli generic drugmaker, worth around $5.3 billion at the time. Under the terms of the deal, Allergan agreed to hold on to the shares for at least one year.

  • Forbes10 months ago

    Bill Ackman's Insider Trading Lawsuit May Cost Pershing Square Investors $75 Million

    Pershing Square is setting aside $75 million to cover a class action insider trading lawsuit surrounding its efforts to merge Allergan with now-embattled Valeant, which made Bill Ackman $1.1 billion according to Forbes.